analyzeportfolio
NYSE · Consumer Staples

MEDIFAST INC (MED)

As-reported financials and SEC filings for MEDIFAST INC. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About MEDIFAST INC

Medifast Inc is a health and wellness company that offers a coach-guided lifestyle system focused on metabolic health and weight management. The company provides scientifically developed products, personalized coaching, and community support to help individuals achieve sustainable metabolic health improvements. Medifast serves clients through a network of independent coaches who guide them in adopting healthy habits and using clinically proven plans and products.

Snapshot

Revenue
$385.8M
Revenue growth (YoY)
-36.0%
Net income
$-18.7M
Diluted EPS
$-1.70
Gross margin
71.3%
Operating margin
-3.7%
Net margin
-4.8%
FCF margin
0.3%
ROE
-9.4%
net income / fiscal-year-end equity
P/E
trailing when available, otherwise FY EPS
Market cap
$136.2M
Long-term debt / equity
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Medifast

  • Revenue fell 36.0% to $386M in FY2025, after a 43.8% decline the year before.
  • Operating margin is now a 3.7% loss in FY2025, from 14.2% in FY2021.
  • Most recent quarter Q2 FY2026: revenue $76M, down 27.6% from Q2 FY2025.
  • Free cash flow was $1M in FY2025, 0.3% of revenue.
  • Net income turned to a $19M loss in FY2025, from a $2M profit in FY2024.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Medifast’s fundamentals sit among the 113 Consumer Staples companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin71.3%
97th percentile of 97
Operating margin-3.7%
27th percentile of 100
Net margin-4.8%
22nd percentile of 105
FCF margin0.3%
28th percentile of 99
Revenue growth (YoY)-36.0%
2nd percentile of 110
ROE-9.4%
28th percentile of 99
Short interest7.42d
84th percentile of 111

Medifast’s revenue growth of -36.0% ranks in the 2nd percentile of the 110 Consumer Staples companies reporting it. Medifast’s gross margin of 71.3% ranks in the 97th percentile of the 97 Consumer Staples companies reporting it.

8 reported insider purchases (code P) totaling $1.4M in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 7 quant / multi-strat books among the superinvestors we track; no conviction manager currently reports a position.

Conviction investors
0
+7 quant / multi-strat
Initiated / added
6
3 new, 3 added
Reduced / exited
1
1 trimmed, 0 exited
Combined position
$18.2M
reported long value
InvestorAs ofPosition valueSharesChange
Renaissance TechnologiesquantQ2 2026$8.3M778.6KAdded
Two Sigma InvestmentsquantQ2 2026$5.1M481.4KAdded
AQR Capital ManagementquantQ2 2026$2.5M236.4KAdded
D. E. ShawquantQ2 2026$979,78092.3KReduced
Citadel AdvisorsquantQ2 2026$597,87356.4KNew
Millennium ManagementquantQ2 2026$508,28347.9KNew
Point72 Asset ManagementquantQ2 2026$222,79921.0KNew

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
8
1 insider
Bought (90d)
$1.4M
code P value
Sells (90d)
0
Reported activity
Net buying
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-26
filed 2026-08-28
Kiai ParsaDirectorBuy42.0K$12.26$515K
2026-08-26
filed 2026-08-28
Kiai ParsaDirectorBuy1.2K$12.26$14K
2026-08-24
filed 2026-08-26
Kiai ParsaDirectorBuy4.2K$12.00$51K
2026-08-24
filed 2026-08-26
Kiai ParsaDirectorBuy118$12.00$1K
2026-08-20
filed 2026-08-21
Kiai ParsaDirectorBuy42.0K$11.60$487K
2026-08-20
filed 2026-08-21
Kiai ParsaDirectorBuy1.2K$11.60$14K
2026-08-19
filed 2026-08-21
Kiai ParsaDirectorBuy28.5K$11.66$333K
2026-08-19
filed 2026-08-21
Kiai ParsaDirectorBuy799$11.66$9K
2026-05-11
filed 2026-05-12
SCHLACKMAN SCOTTDirectorBuy2.5K$12.53$31K
2026-05-08
filed 2026-05-12
SCHLACKMAN SCOTTDirectorBuy2.5K$12.65$32K

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
1.8M
settled 2026-08-14
Change vs prior
+22.9%
vs previous settlement
Days to cover
7.42
at avg daily volume
Avg daily volume
245.8K
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-141.8M+22.9%7.42
2026-07-311.5M-9.5%9.16
2026-07-151.6M+5.0%9.41
2026-06-301.6M-27.6%3.69
2026-06-152.2M-0.9%15.34
2026-05-292.2M-0.5%10.16
2026-05-152.2M+7.6%9.33
2026-04-302.0M-6.1%13.19

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$385.8M$602.5M$1.07B$1.60B$1.53B
Gross profit$275.2M$444.6M$775.9M$1.14B$1.13B
Operating income$-14.2M$2.9M$126.4M$184.8M$216.2M
Net income$-18.7M$2.1M$99.4M$143.6M$164.0M
Diluted EPS$-1.70$0.19$9.10$12.73$13.89

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2025FY2024FY2023FY2022FY2021
Cash and equivalents$89.3M$90.9M$94.4M$87.7M$104.2M
Current assets$201.7M$214.4M$224.0M$222.8M$306.9M
Total assets$248.0M$284.2M$309.9M$316.2M$398.3M
Current liabilities$43.0M$64.2M$92.3M$140.9M$169.8M
Long-term debt
Total liabilities$49.1M$74.1M$108.4M$161.2M$195.9M
Total equity$198.9M$210.1M$201.5M$155.0M$202.5M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$6.9M$24.5M$147.7M$194.6M$94.5M
Capital expenditure$5.6M$7.5M$6.5M$16.7M$34.2M
Free cash flow$1.2M$17.0M$141.2M$177.9M$60.3M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$76.4M-27.6%$-3.1M$-0.28
Q1 FY2026$76.0M-34.3%$-2.1M$-0.19
Q4 FY2025$75.1M-36.9%$-18.1M$-1.65
Q3 FY2025$89.4M-36.2%$-2.3M$-0.21
Q2 FY2025$105.6M-37.4%$2.5M$0.22
Q1 FY2025$115.7M-33.8%$-772,000$-0.07
Q4 FY2024$119.0M-37.7%$801,000$0.07
Q3 FY2024$140.2M-40.6%$1.1M$0.10

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNYSE
SectorConsumer Staples
SIC industryMiscellaneous Food Preparations & Kindred Products
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2007
SEC CIK910329

Selected SEC filings

10-K2026-02-17
View on EDGAR →
10-Q2026-08-03
View on EDGAR →
10-Q2026-05-04
View on EDGAR →
10-Q2025-11-03
View on EDGAR →
10-Q2025-08-04
View on EDGAR →
8-K2026-08-03
View on EDGAR →
8-K2026-07-17
View on EDGAR →
8-K2026-06-01
View on EDGAR →

Largest Consumer Staples peers

All Consumer Staples companies →

Monitor MED

Get an alert when Medifast files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor MED free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.